cyrilzakka/clinical-trials huggingface dataset:
Airway Management Via the Retromolar Route Access

Is there a difference in vocal cord visualization between the retromolar and conventional access?

Management of the difficult airway is still an essential part of modern anaesthesia. Up to now, there have bee no clinical investigations comparing the intubation method via the retromolar route (RM), with the conventional intubation route (CM).

For the present clinical investigation, 100 patients undergoing elective surgery will be investigated in the General Hospital of Vienna when for the anaesthesia intubation is required. In both intubation methods (RM and CM) the anaesthesiologist will visually determine the Cormack \& Lehane score in a randomly assigned sequence with and without a BURP-manoeuvre (= backwards, upwards and rightwards pressure). Thereafter intubation is performed in all patients by the CM method and if intubation fails the RM technique will be used. Of course, as per usual, every intubation trial is interrupted by a 20 second 100%-oxygen-ventilation period to reach a pulse oximetry oxygen saturation of at least 97% SpO2. Thereafter, if intubation fails again every other intubation technique will be applied, as necessary and called for.

Eligibility Criteria:
Inclusion Criteria:

* Age \> 18yr
* BMI \< 30kg/m2
* Elective surgery
* Absence of at least one molar of the right mandible

Exclusion Criteria:

* Emergency patients
* Prevalence of reflux disease
* Toothless patients
* Diaphragmatic hernia
* Patient is not sober
* Ventilation problems during induction of anaesthesia
* Gastric regurgitation during induction of anaesthesia
* Patient with a tracheostomy
Rationale and Analysis of the Use of ETDNO in the Treatment of PIPJ Flexion Contracture:

Introduction: Flexion contracture is one of the most frequent complications in finger trauma. The use of orthoses to obtain the best total end range time (TERT) is the most popular method to treat this pathology . Until now, no orthosis applied for longer than 3 weeks had been able to achieve TERT longer than 12 hours.

Purpose of the study: To assess whether the elastic tension digital neoprene orthosis (ETDNO), using a serial dynamic program, can achieve a better result in ROM and TERT than other orthoses described in the literature.

Methods: analysis of outcomes in a sample of 30 patients with PIP joint flexion contracture treated with the ETDNO and serial dynamic program.

In this study the researcher will compare the efect of daily TERT treatment on the proximal interphalangeal joint contracture using an ETDNO. The investigator will treat two different groups one with a dose of from 11 to 13 hours of the ETDNO while the other one is treated with a dose of from 20 to 22 hours of daily TERT with the same device. This treatment will last three weeks and will be evalauted the first day, the he first week and the third week. At the end of the study the researcher will quantify the improvement on both groups to know which dailyTERT dose is the best option.

Eligibility Criteria:
Inclusion Criteria:

* PIP flexion contracture

Exclusion Criteria:

* more than 6 month of contracture and more than 45º of flexion contracture
YAG Laser Vitreolysis for Floaters

Vitreous fluid, containing 95% water, fills the space behind the lens. Its gelatinous consistency is due to the presence of hyaluronic acid, mucopolysaccharide and collagen fibers. With age, the collagen aggregates into parallel bundles, bound by cross links, leaving the pockets of liquid in the glass body. This redistribution is referred to as syneresis, which is found in 90% older than 40 years. After liquefaction, the vitreous enters the retroviral space and separates the posterior hyaloid membrane from the retina. When separating from the optical disk it forms an annular formation (Weiss ring) in front of the optical disc. These agglomerated collagen bundles (opacities) disperse the photons of light and are perceived by the patients as a "gray silhouette-like artifact". Two major interventions for these symptoms include Nd: YAG laser vitreolysis and vitrectomy. The less invasive method Nd: YAG laser increases the temperature of the opacity thus vaporizing them to smaller fragments that are easier to sediment onto the bottom of the vitreous cavity thereby relieving the symptoms.


Eligibility Criteria:
Inclusion Criteria:

* Age 18 years or older
* Is able to give written informed consent to the procedure
* Patients with clinical symptoms of floaters and clinically confirmed diagnosis of opacity in the vitreous body.

Exclusion Criteria:

* Inability to tolerate the procedure
* Blurred anterior eye segment
* Cataract or Intraocular lens opacity
* Blurred posterior eye segment
* Active eye inflammation
* Iris synechiae
* Uncontrolled intraocular pressure elevation
* Peripheral retinal degeneration
NITI CAR27 (ColonRing) Compression Anastomosis in Colorectal Surgery

After resection of diseased segments of the large intestine, the continuity of the intestine has to be restored. This can be done by suturing or with so called stapling devices. In addition since 2 centuries compression rings are used to connect the intestine after resection. The NITICAR27 device is a novel compression anastomosis device. The investigators want to prove if this novel device can be compared to commonly used stapling devices concerning anastomotic leakage, bleeding and stenosis.


Eligibility Criteria:
Inclusion Criteria:

* benign and malign lesions of the colon and rectum

Exclusion Criteria:

* advanced peritonitis (putrid, feculent)
Treatment of Major Depressive Disorder Post Stroke With Transcranial Direct Current Stimulation

Stroke is one of the main public health problems in America Latina. It can be associated with several neuropsychiatric complications, which include a broad spectrum of emotional distress and cognitive, results in important clinical implications for the prognosis of these patients. Depression is a common complication, affecting around 5-72% of patients and is associated with various cognitive deficits and also with increased mortality - up to 50% more deaths compared to non-depressed patients. Treatment of depression after stroke is important not only to improve depressive symptoms but can also be beneficial for cognitive deficits, activities of daily living. and leads to increased survival for these patients. There are different treatments for depression after stroke, all showing inconclusive results, even though antidepressants have been effective in some groups of patients, tolerability and treatment adherence were not very good-so it is necessary that new therapeutic modalities are presented with good tolerability. In this sense, transcranial direct current stimulation (tDCS) is an interesting technique that can provide interesting results, which proved to be effective for depression in some studies. This study proposes to investigate the effect of tDCS for the treatment of major depressive disorder after stroke. The proposed design is a clinical trial, randomized, double-blind, placebo-controlled study in a subsample of participants in the prospective cohort of stroke: Study of Morbidity and Mortality of stroke. They will be allocated to one of the groups: sham or active tDCS group. Participants will receive ten consecutive days of active or sham stimulation and return at the end of two weeks to evaluate the improvement in depression, cognition and functionality. As objectives, the investigators expect to see a clinical improvement of depression through scales like Hamilton, Beck and MADRS(Montgomery-Asberg Depression Rating Scale), and expect improvement on cognitive tests as MoCA (Montreal Cognitive Assessment), MMSE (mini mental scale exam), FAB (frontal assessment battery) and trail test. Another goal is to see improvement in markers related to depression as BDNF, cortisol, interleukins and heart rate variability. With all this, the investigators hope to offer a new treatment, and effective with few side effects to treat depression after stroke.

The Study of Morbidity and Mortality of stroke (EMMA) is a cohort study of patients with stroke.

Eligibility Criteria:
Inclusion Criteria:

* Major Depressive Disorder after stroke
* First episode of Stroke
* Hamilton \> 17

Exclusion Criteria:

* Others severe neurologic conditions
* Others Axis I besides anxiety
* Important suicidal ideation
* Use of antidepressants
Clinical Trial of Measles, Mumps and Rubella Combined Vaccine, Live

To evaluate the immunogenicity, lot-to-lot consistency and safety of three consecutive batches of Measles, Mumps and Rubella Combined Vaccine, Live.

To assess Measles Mumps and Rubella Combined Vaccine, Live, (MMR) lot-to-lot consistency in healthy Chinese Children at the age of 8-12 months, and the participants randomized to receive one injections of 0.5 mL Measles, Mumps and Rubella Combined Vaccine, Live at day 0.

Eligibility Criteria:
Inclusion Criteria:

Provide vaccination certificate and birth certificate for healthy children aged 8-12 months;

* Volunteers' legal guardian informed consent, volunteered to participate and signed an informed consent form；
* The volunteer's legal guardian has the ability to understand the research procedures, use the thermometer, scale and fill in the diary card as required, and can complete the clinical study in accordance with the requirements of the clinical trial protocol.

Exclusion Criteria:

* The axillary body temperature on the day of enrollment was more than 37.0 ℃;
* Have suffered from measles, mumps and rubella in the past or are suffering from measles, mumps and rubella;
* Any previous vaccination containing measles, mumps and rubella;
* Persons known to be allergic to any ingredient in the investigational vaccine;
* Any previous history of vaccine or drug allergy;
* Premature (delivered before the 37th week of pregnancy) and low weight (birth weight \< 2500g);
* History of dystocia, asphyxia rescue and nervous system damage;
* Congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc;
* Acute disease, serious chronic disease or acute attack of chronic disease on the day of vaccination;
* Have a history of live attenuated vaccine within 28 days before vaccination and other vaccines within 7 days;
* Those who receive immune enhancement or inhibitor treatment within 3 months (continuous oral or drip for more than 14 days);
* Suffering from congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia or other autoimmune diseases;
* History of asthma, unstable in the past two years, requiring emergency treatment, hospitalization, intubation, oral or intravenous corticosteroids;
* Have received blood or blood related products;
* Patients with progressive nervous system diseases have a history of convulsion, epilepsy, encephalopathy, GuillainBarre syndrome, mental history or family history;
* Have a history of abnormal coagulation function (such as coagulation factor deficiency and coagulation diseases);
* Plan to move out before the end of the study or leave for a long time during the scheduled study visit;
* Participating in or planning to participate in other clinical trials in the near future;
* The investigator judges any situation that is not suitable to participate in this clinical trial.
Effects of Secondhand Smoke on Flight Attendant Health

This is a study on a population of flight attendants who were exposed to occupational secondhand tobacco smoke (SHS). This research will examine associations between flight attendant SHS exposure and development of respiratory illnesses, reproductive problems, and cardiovascular diseases.

The main hypothesis of this study is that exposure to the secondhand tobacco smoke (SHS) in the confined workspace of commercial aircraft prior to the ban of cigarette smoking is responsible for long-term damage on the health of nonsmoking flight attendants. We will compare the data collected from our pre-ban flight attendant participants to age-matched, nonsmoking controls from the NHANES (National Health and Nutrition Examination Survey) database. The results of our study should permit us to determine if SHS exposure is the cause of long-term increased cardiovascular morbidity and risk, as well as increased susceptibility to respiratory illnesses.

Eligibility Criteria:
Inclusion Criteria:

1. Never smoker flight attendants who began working for airlines before the smoking ban on aircrafts went into effect. Never smoker is defined as those with history of tobacco use of less than 100 cigarettes in their lifetime.
2. SHS exposure for at least 1 year while working with the airlines.

Exclusion Criteria:

1. Less than 1 year of occupational exposure to SHS
2. Smoking more than 100 cigarettes over a lifetime
Effects of Nutritional Counseling on Nutritional Status and Quality of Life of Head and Neck Cancer Patients

This study investigates the effects of nutritional counseling versus standard nutritional care on nutritional status and quality of life in patients with head and neck cancer submitted to radiotherapy.Half participants will receive intensive nutritional counseling while the other half will receive standard care.

Considering that head and neck cancer patients usually present reduced food intake with consequent involuntary weight loss and significant worsening of quality of life, this study investigates the effects of nutritional counseling versus standard nutritional care on nutritional status and quality of life in patients with head and neck cancer submitted to radiotherapy.

Half participants (45) will receive intensive nutritional counseling, that is, once they are admitted to the study and once a week during radiotherapy, following the protocol of nutritional care to cancer patients in radiotherapy proposed by the American Dietetic Association (ADA).

The other half (45) will receive standard care, that is, nutritional counseling / education performed by hospital nurses and nutritional care performed by the hospital nutritionist (when there is a demand, usually 1 to 2 times during oncologic treatment).

Eligibility Criteria:
Inclusion Criteria:

* Patients with head and neck cancer (oral cavity, oropharynx, hypopharynx and larynx); both sexes; aged 18 years and over, submitted to radiotherapy after chemotherapy or radiotherapy as a first-choice treatment or as adjuvant treatment (post-surgical).

Exclusion Criteria:

* Patients using parenteral nutrition; without cognitive ability to understand the concepts of the questionnaires; in palliative radiotherapy.
The TELEAP1 CPAP-telemonitoring Study

TELEAP1 is a multicenter cohort pilot-study designed to evaluate the impact of a published SFRMS/SPLF CPAP-telemonitoring diagnosis/therapeutic algorithm on the CPAP-compliance of newly treated patients with obstructive sleep apnea..

Continuous Positive Airway Pressure (CPAP)-devices can track compliance, but also leaks and residual Apnea-Hypopnea-Index (AHIflow) values. CPAP tracking systems seem intuitively useful, but there are few data demonstrating the benefit of such systems in improving CPAP-compliance and/or patients quality of life.

In 2020, a working group from the Société Française de Recherche et de Médecine du Sommeil (SFRMS) and the Société de Pneumologie de Langue Française (SPLF) have proposed a CPAP-telemonitoring diagnosis/therapeutic algorithm for newly treated patients with obstructive sleep apnea.

In order to describe and evaluate the impact of this SFRMS/SPLF-algorithm (not only on the patient but also on the home care provider activity), a one year multicenter cohort pilot-study (TELAP1-study) was set up.

Eligibility Criteria:
Inclusion criteria:

* 18 years of age or older
* Patient newly CPAP-treated and eligible for care and for the reimbursement by the French Social Security rules
* Signed informed consent

Exclusion criteria:

* Previous CPAP-treatment
* Pregnancy
* Inability to understand the nature and aims of the study or to communicate with the investigator
* Simultaneous participation in another trial with an exclusion clause to participate in another trial
* No affiliation with the French social security regime
* Loss of personal capacity resulting in state protection
* Deprivation of liberty by judicial or administrative decision
Secondary Lymphedema Due to Human Adjuvant Disease

This observational, descriptive, retrospective study the clinical and imaging findings of 10 lower legs of 5 patients with previous history of injection of modeling substances for cosmetic purposes at buttocks and hips ande developed lower limb edema. Lower limb lymphedema index and lymphoscintigraphy findings were evaluated and reported.

Lymphoscintigraphy findings were reported with the Transport index (TI), were any value over 5 will represent abnormalities in lymphatic function.

Eligibility Criteria:
Inclusion Criteria:

* Both sex
* Over 18 years old
* History of injection of modelling substances for cosmetic purposes
* History of lower limb edema

Exclusion Criteria:

* History of primary lower limb lymphedema
* Reject to participate
* Confirmed other causes of edema
OPTImal PALliative Anti-epidermal Growth Factor Receptor Treatment in Metastatic Colorectal Cancer -

The present study will investigate the feasibility and clinical value of using circulating tumor DNA as selection for anti-epidermal growth factor receptor treatment for metastatic colorectal cancer.

The primary aim of this prospective study is to investigate if cfDNA in plasma is feasible and reliable for selection of mCRC patients who will benefit of anti-EGFR monoclonal antibody therapy

Secondary, to analyze developments in mutational status as reflected by cfDNA in plasma during therapy and at time of progression

Eligibility Criteria:
Inclusion criteria

* Histopathologically verified metastatic colorectal cancer
* Indication for systemic palliative treatment with standard Anti-EGFR monoclonal antibodies
* Fit for therapy with EGFR inhibition
* Consent to treatment and sampling
* Measureable disease according to RECIST v 1.1
* Age ≥ 18

Exclusion criteria

* PS \> 2
* Significant other cancer disease within 5 years of inclusion
* Conditions precluding sampling during therapy and treatment breaks.
Trans-catheter Chemo-embolization Combined With rAd-p53 Gene Injection in Treatment of Advanced Hepatocellular Carcinoma

Treatment options for advanced hepatocellular carcinoma (HCC) are limited due to patients' poor condition, advanced tumor, concomitant intra- and extra-liver diseases, and resistance to both chemo- and radio-therapy. Trans-catheter embolization (TAE) or Trans-catheter chemo-embolization (TACE) is the most widely used locoregional treatment for advanced HCC. But no solid evidences support the beneficial effect of the chemotherapy in TACE. Many advanced HCC patients also can't tolerate the locoregional chemotherapy. The p53 gene has multiple anticancer functions and does not have any of the immune-inhibitory effects of chemo- or radio-therapy. The objectives of this study are to investigate the efficacy and safety usingTAE plus recombinant adenoviral human p53 gene (rAd-p53) in treatment of advanced HCC.

Study design: multicenter, open-labeled, active-controlled phase II study

Study treatments: TACE combined with rAd-p53 injection vs.TACE. The treatments are given once per 21 days until the disease progression. For the experiment group, 2 X 1000,000,000,000 viral particles of rAd-p53 will be injected into the embolization artery.

Study objectives: efficacy and safety of the study treatments

Study endpoints: safety (adverse events, vital signs, lab tests, ECG and physical examination) and efficacy (progression-free survival, overall survival, and ECOG PS)

Eligibility Criteria:
Inclusion Criteria:

1. histopathologically diagnosed HCC;
2. unresectable;
3. over 18 years old;
4. with an Eastern Cooperative Oncology Group (ECOG) score of 0-2;
5. with Barcelona Clinic Liver Cancer (BCLC) Stage of B or C;
6. with Child-Pugh score A or B;
7. with normal tests of hemogram, blood coagulation, liver and kidney function; 8. signed the informed consent form.

Exclusion Criteria:

1. Serious blood coagulation disorder, bleeding tendency, platelet \< 6 \* 1000000000/L;
2. have serious heart, lung function abnormalities or severe diabetes patients;
3. active infection;
4. liver function Child-Pugh grade C;
5. secondary and diffuse hepatocellular carcinoma patients;
6. extensive metastasis;
7. severe atherosclerosis;
8. AIDS patients;
9. serious thrombotic or embolic events within 6 months;
10. renal insufficiency requiring hemodialysis or peritoneal dialysis;

12. pregnant or lactating women;

13. mental disorder or disease.
Food Effect Study of DDO-3055 Tablets in Healthy Subjects

The study is a randomized , open-label, two-stage crossover food effect study of single doses of DDO-3055 tablets in healthy subjects. 14 healthy subjects were randomly divided into groups A and B, 7 subjects in each group. Two stage washout period is 6 days.


Eligibility Criteria:
Inclusion Criteria:

* 1. Healthy male volunteers, aged 18\~45.
* 2. Body weight ≥ 50 kg, body mass index (BMI) between 18 to 28.
* 3. Hemoglobin is in the normal range.
* 4. Signed informed consent.

Exclusion Criteria:

* 1. Vital signs, physical examination, laboratory results are abnormal and clinically significant.
* 2. Currently suffering from cardiovascular, liver, kidney, digestive, nervous, blood, thyroid or mental diseases.
* 3. Suspected allergy to the active ingredient or excipient of the experimental drug.
* 4. Have used erythropoietin within 1 month prior to screening or are currently using erythropoietin.
* 5. Had donated blood or blood transfusion within 3 months prior to screening.
* 6. Vein blood collection is difficult or physical condition can not afford blood collection.
* 7. Hepatitis b virus surface antigen (HBsAg), hepatitis c virus antibody (HCVAb), Syphilis antibody, human immunodeficiency virus antibody (HIVAb)were positive.
* 8. Average daily smoking ≥5 cigarettes within 3 months before screening; average daily intake of alcohol within one week is more than 15g (15g alcohol is equivalent to 450mL beer or 150mL wine or 50mL low-alcohol liquor);or 2 days before taking the study drug and during the trial take the tobacco and alcohol and caffeinated foods or drinks, and have special dietary requirements and cannot follow a uniform diet.
* 9. 3 months prior to screening involved in any drug or medical device clinical trials, or within 5 half-life of drugs before screening.
* 10. Any health care products, Over-the-counter drugs or prescription drugs that affects the absorption, distribution, metabolism and excretion of the experimental drug was used within 1 month before the administration.
* 11. With a history of drug abuse or screening visit/baseline visit urine drug abuse screening positive.
* 12. Subjects who are unwilling to take contraceptives or who are likely to donate sperm during the trial and within 30 days after administration; or who do not agree to physical contraception during the trial.
* 13. Other conditions in which the study physician considered the subject not suitable for the trial.